



BioFacilities News / Updates

Tracking news/trends in the biologics industry; 100s of sources filtered by our analysts; 20+ years' experience. Your Source for Biologics industry news and trends.

Inside this edition:

- Pfizer spending USD \$500 MIL for new gene therapy facility in North Carolina, USA
- Kite Pharma constructing new cell therapies facility in Maryland, USA
- Aldevron constructing new cell and gene therapy viral vector site in North Dakota, USA
- Ampersand Capital Partners acquires Vibalogics (Cuxhaven, Germany)

Pfizer is spending \$500 million to expand its gene therapy manufacturing facilities in Sanford, North Carolina, USA, and plans to have a staff of 300. *Bloomberg News, Aug. 21, 2019*

Kite Pharma, a subsidiary of Gilead Science, is constructing a new 279,000 sq. ft. cellular therapies manufacturing facility in Urbana, Maryland, USA, with the site expected to have 400-800 staff. The co.'s current product, Yescarta, will be among the products manufactured. The co. is also constructing a 67,000 sq. ft. gene therapy viral vectors manufacturing facility in Oceanside, California, USA. *Source: Frederick News-Post, Aug. 8, 2019 and FiercePharma July 16, 2019*

Aldevron is constructing a new 14 acre campus in Fargo, North Dakota, USA, for GMP manufacture of cellular and particularly gene therapy viral vectors, related enzymes and other biologics, increasing the size of what is already the "world's largest plasmid DNA manufacturing facility," and expanding the co.'s manufacturing capacity 10x. *Source: Aldevron press release, June 3, 2019*

Click below to reserve your **FREE** copy of our 2019 **Top Trends in Biopharmaceutical Manufacturing White Paper**.

We highlight the top trends for 2019 in biopharmaceutical manufacturing, capacity and production.

[Click Here to Reserve Your Free Top 15 Trends White Paper](#)

Additional BioFacilities News

lovance Biotherapeutics is constructing a USD \$75 MIL, 136,000 sq. ft. cellular therapies

commercial manufacturing facility in Philadelphia, Pennsylvania, USA. *Source: Philadelphia Inquirer, Sept. 3, 2019*

Orchard Therapeutics is constructing a 150,000 square-foot plant in Fremont, California, USA, for manufacture of its viral vector gene therapies. *Source: BioProcess Intl., Aug. 16, 2019*

GlaxoSmithKline is expanding its facilities in Hamilton, Montana, USA, for manufacture of the bacterial-derived adjuvant (MPL) used in its Shingrix human papillomavirus (HPV) vaccine. Capacity will be in the high 10s of million doses/year. *Source: FiercePharma, April 24, 2019*

After selling its interest in Brammer Bio to Thermo Fisher for USD \$1.7 BIL, **Ampersand Capital Partners** acquired Vibalogics, Cuxhaven, Germany, a leading European viral vector/gene therapy CMO. *Source: FiercePharma, May 30, 2019*

Vibalogics (Cuxhaven, Germany) announced expansion of its oncolytic gene therapies manufacturing CMO facilities, including adding 50 and 200 L bioreactors and a Siemen's process control system. (All announced prior to recent acquisition.) *Source: BioPharma-Reporter.com, May 9, 2019*

Pall (Danaher) is constructing two cellular/gene therapy technology facilities in New Jersey, USA, the Cell and Gene Therapy Development Center, with a focus on process development, and the Center for Advanced Biologics Manufacturing, with a focus on continuous gene therapy viral vectors. *Source: Danaher press release, March 29, 2019*

Catalent, which acquired gene therapy vector company Paragon for over USD \$1 BIL, recently acquired two clinical development and manufacturing facilities in Gaithersburg, Maryland, USA from vaccines' co. Novavax. 100 current staff will be shifted to Paragon and its viral vector/gene therapies CMO operations. *Source: Novavax press release, June 27, 2019*

Irvine Scientific, subsidiary of FujiFilm, is constructing a 250,000 sq. ft. animal components-free powder and liquid culture media manufacturing facility in Tilburg, The Netherlands. Capacity will be 320,000 Kg/year of powders and 470,000 L/year of liquid media. *Source: BioPharma-Reporter.com, July 2, 2019*

Fuji Diosynth (CMO; Billingham, UK) is constructing a new continuous manufacturing facility that will use proprietary process control methods upstream and "disruptive" downstream operations. The fully single-use facility will include a 500 L perfusion bioreactor and seven downstream processing units. *Source: BioPharma-Reporter.com, June 11, 2019*

Sartorius Stedim expanded its bioprocessing supplies manufacturing facility in Yaucon, Puerto Rico. Filters have been produced there since 1982 and single-use bags/films since 2012. *Source: Pharma's Almanac, July 2, 2019*

StmoniX opened new facilities in La Jolla, California, USA, for high-throughput screening using a microOrgan stem cell platform. *Source: Outsourcing-Pharma.com, July 9, 2019*

Cryoport, a cold chain logistics co., acquired Cryogene, including a 21,000 sq. ft. biologics storage facility in Houston, Texas, USA. *Source: BioPharma-Reporter.com, May 23, 2019*

CinnaGen ilaç (Tekirdag, Turkey) is a new USD \$100 MIL bioprocessing facility constructed by CinnaGen Pharmaceutical Group (Iran). This is the first recombinant biologics manufacturing facility in Turkey, and the first expansion of an Iranian “knowledge-based factory” outside of Iran. *Source: Tehran Times, June 22, 2019*

Paragon Gene Therapy (Baltimore, MD) (Catalent Pharma), is constructing a dedicated clinical and commercial manufacturing facilities for Passage Bio (Philadelphia, PA) with manufacturing using iCellis bioreactors from Pall, Danaher. *Source: Contract Pharma, June 10, 2019*

Precision BioSciences, Inc. opened a new cellular/gene therapies GMP clinical manufacturing facility in Durham, North Carolina, USA. *Source: North Carolina Biotechnology Center press release, July 18, 2019*

Cellonics (CMO; Heidelberg, Germany) is investing USD \$56 million in construction of 2,000 sq. meters of new cellular and gene therapies Phase III and commercial manufacturing facilities at facilities formerly owned by Syngenta. The facility will include 6 x 2,000 L bioreactors and a 1,000 L perfusion bioreactor. *Source: BioProcess Intl., July 5, 2019*

Anemocyte opened a new plasmid/viral vector gene and cellular therapy CMO manufacturing facility in Gerenzano, Italy, using modular cleanrooms, with this the most advanced cellular/gene therapies manufacturing facility in Italy. *Source: Anemocyte press release, July 16, 2019*

HALIX (CMO; Leiden, The Netherlands) is constructing a 6,700 sq. meter viral vectors (gene therapies) and vaccines facility, including 1,000 L bioreactors. *Source: B3C Newswire, Aug. 9, 2019*

PTC Therapeutics, a gene therapy developer, recently signed a long-term lease from Bristol-Myers Squibb for its 185,000 sq. ft. R&D and manufacturing facilities in Hopewell, New Jersey, USA. *Source: FiercePharma, Aug. 7, 2019*

BioPlan Publications


Updated! Last Chance to order! **16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production**

The 2019 16th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production is the most recent study of biotherapeutic developers and contract manufacturing organizations' current and projected future capacity and production.

This report's 485 pages of data-rich analysis will help improve your decision-making in biomanufacturing operations, with in-depth analysis of capacity, production trends, benchmarks, and much more.

Published by BioPlan Associates, Inc., April 2019, ISBN 978-1-934106-36-5

[Order Your Copy Today!](#)



Questions? Comments? Let us know. Our interest is to provide you the highest value information and service available.

If you require custom research, BioPlan Associates, Inc., has been delivering actionable market data and customer analysis to the biopharma and life sciences industries for 30 years.

Contact us for a free evaluation and research proposal. info@bioplanassociates.com

